ScholarIQanswers from OpenAlex & ORCID
Shukui Qin
ResearcherPublications, citations & collaboration network
Shukui Qin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Shukui Qin have?
ScholarIQindexed works
Shukui Qin has 558 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Shukui Qin have?
ScholarIQcitation count
Shukui Qin has 51,959 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Shukui Qin?
ScholarIQh-index
Shukui Qin has an h-index of 76 in OpenAlex.
What is the i10-index of Shukui Qin?
ScholarIQi10-index
Shukui Qin has an i10-index of 235 in OpenAlex.
What is the ORCID of Shukui Qin?
ScholarIQorcid
The ORCID for Shukui Qin is on the source record.
What is the OpenAlex record for Shukui Qin?
ScholarIQopenalex
The OpenAlex for Shukui Qin is on the source record.
What are the most-cited papers on Shukui Qin?
ScholarIQmost cited works
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Rui‐Hua Xu, Zhehai Wang, Qiong Wang, Xuenong Ouyang, Yan Yang, Yi Ba, Jun Liang, Xiaoyan Lin, Deyun Luo, Rongsheng Zheng, Xin Wang, Guoping Sun, Liwei Wang, Leizhen Zheng, Hong Guo, Jingbo Wu, Nong Xu, Jianwei Yang, Honggang Zhang, Ying Cheng, Ningju Wang, Lei Chen, Zhining Fan, Piaoyang Sun, Hao Yu
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li, Shukui Qin, Rui‐Hua Xu, Thomas Yau, Brigette Ma, Hongming Pan, Jianming Xu, Yuxian Bai, Yihebali Chi, Liwei Wang, Kun‐Huei Yeh, Feng Bi, Ying Cheng, Anh T. Le, Jen-Kou Lin, Tianshu Liu, Dong Ma, Christian Kappeler, J. Kalmus, Tae Won Kim
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson, Shukui Qin, Joong‐Won Park, Ronnie T.P. Poon, Jean‐Luc Raoul, Philip A. Philip, Chih‐Hung Hsu, Tsung‐Hui Hu, Jeong Heo, Jianming Xu, Ligong Lu, Yee Chao, Éveline Boucher, Kwang‐Hyub Han, Seung Woon Paik, Jorge Alberto Robles-Aviña, Masatoshi Kudo, Lünan Yan, Abhasnee Sobhonslidsuk, Д. В. Комов, Thomas Decaens, Won Young Tak, Long‐Bin Jeng, David Liu, Rana Ezzeddine, Ian Walters, Ann‐Lii Cheng
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Călin Cainap, Shukui Qin, Wen‐Tsung Huang, Ik Joo Chung, Hongming Pan, Ying Cheng, Masatoshi Kudo, Yoon‐Koo Kang, Pei‐Jer Chen, Han-Chong Toh, Vera Gorbunova, Ferry A.L.M. Eskens, Jiang Qian, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, Saied El-Nowiem